| 24th Feb 2023 11:00 am |
RNS |
Director/PDMR Shareholding |
| 23rd Feb 2023 7:00 am |
RNS |
AstraZeneca enters agreement with KYM for CMG901 |
| 22nd Feb 2023 7:10 am |
RNS |
Filing of Form 20-F with SEC |
| 21st Feb 2023 11:00 am |
RNS |
Annual Financial Report |
| 13th Feb 2023 2:01 pm |
RNS |
Director/PDMR Shareholding |
| 13th Feb 2023 2:00 pm |
RNS |
Director/PDMR Shareholding |
| 9th Feb 2023 7:00 am |
RNS |
Final Results |
| 1st Feb 2023 3:00 pm |
RNS |
Total Voting Rights |
| 26th Jan 2023 6:15 pm |
RNS |
Update on Evusheld US EUA |
| 16th Jan 2023 7:00 am |
RNS |
Acquisition of Neogene Therapeutics completed |
| 11th Jan 2023 1:00 pm |
RNS |
Airsupra (PT027) approved in US for asthma |
| 9th Jan 2023 7:00 am |
RNS |
AstraZeneca acquire CinCor for cardiorenal asset |
| 3rd Jan 2023 3:00 pm |
RNS |
Total Voting Rights |
| 30th Dec 2022 11:00 am |
RNS |
Director/PDMR Shareholding |
| 28th Dec 2022 7:05 am |
RNS |
Calquence Japan approval for treatment-naïve CLL |
| 28th Dec 2022 7:00 am |
RNS |
Imfinzi, Imjudo approved in Japan for 3 cancers |
| 21st Dec 2022 7:05 am |
RNS |
Lynparza approved in EU for prostate cancer |
| 21st Dec 2022 7:00 am |
RNS |
Imfinzi approved in EU for biliary tract cancer |
| 19th Dec 2022 7:20 am |
RNS |
Enhertu recommended for EU approval in HER2-low BC |
| 19th Dec 2022 7:15 am |
RNS |
Enhertu approved in EU for gastric cancer |
| 19th Dec 2022 7:10 am |
RNS |
Imfinzi + Imjudo recommended for approvals in EU |
| 19th Dec 2022 7:05 am |
RNS |
Update on Imfinzi PEARL trial |
| 19th Dec 2022 7:00 am |
RNS |
Forxiga CHMP opinion for symptomatic chronic HF |
| 15th Dec 2022 7:00 am |
RNS |
Update on US review of Lynparza PROpel sNDA |
| 8th Dec 2022 1:30 pm |
RNS |
Capivasertib PFS in HR-positive breast cancer |
| 1st Dec 2022 3:00 pm |
RNS |
Block listing Interim Review |
| 1st Dec 2022 3:00 pm |
RNS |
Total Voting Rights |
| 30th Nov 2022 7:05 am |
RNS |
AstraZeneca announces sale of West Chester site |
| 29th Nov 2022 7:00 am |
RNS |
AstraZeneca to acquire Neogene Therapeutics |
| 23rd Nov 2022 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 14th Nov 2022 7:10 am |
RNS |
Enhertu recommended for EU approval in gastric |
| 14th Nov 2022 7:05 am |
RNS |
Imfinzi recommended for approval in the EU for BTC |
| 14th Nov 2022 7:00 am |
RNS |
Lynparza combo recommended in the EU for mCRPC |
| 11th Nov 2022 7:00 am |
RNS |
Imfinzi + Imjudo approved in US for lung cancer |
| 10th Nov 2022 7:00 am |
RNS |
YTD and Q3 2022 Results |
| 9th Nov 2022 7:00 am |
RNS |
FDA Advisory Committee recommends PT027 in asthma |
| 4th Nov 2022 7:00 am |
RNS |
Beyfortus (nirsevimab) approved in EU |
| 1st Nov 2022 3:00 pm |
RNS |
Total Voting Rights |
| 26th Oct 2022 7:00 am |
RNS |
Capivasertib Phase III trial met primary endpoints |
| 25th Oct 2022 7:00 am |
RNS |
Update on MESSINA Phase III trial |
